Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis B, Chronic: Entecavir (NICE)
You must be a registered user to access the content and receive email bulletins from Healthcare Republic. If you have a paid subscription to MIMS or MIMS for Nurses, please activate your subscription. Otherwise, complete the free registration by choosing

Genelabs, NHRI collaborate on hepatitis C drug candidates
REDWOOD CITY, Calif.- has entered into a collaborative research agreement with the to discover and develop compounds that target the hepatitis C virus (HCV). HCV drug candidates will be developed using Genelabs' lead compounds on an existing target the

UPDATES AND COMMENTARY RSS Feed

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Vertex's Advanced Trial Could Change HCV Treatment
Hundreds of non-responders to interferon-ribavirin combination therapy will be enrolled in a late stage clinical trial for Vertex's telaprevir....

Silymarin Improves Quality of Life During Hepatitis C Treatment
Although a large-scale study concluded long-term interferon therapy to be ineffectual for Hepatitis C management, it demonstrated improvements in quality of life for participants supplementing with silymarin....

Hepatitis C Virus RNA Profiles in Chronically Infected Individuals: Do They Relate to Disease Activity?

table  1.   Histological Features Observed in Chronic HCV Patients in Relation to Transaminase Profile and Viremia Levels

Minimal
Changes
Mild
CH
Moderate
CH
Severe
CH
P

ALT pattern over 12 months
  Normal ALT 3 15  5 0 .012
  Fluctuating 0 10 15 1
HCV-RNA fluctuations
  delta < 0.5 Log 3/3  3/15 3/12 0 NS
  delta greater than 0.5 Log 0 12/15 9/12 1/1

NOTE.   delta represents the difference between the maximum and minimum value of HCV RNA measured over time in each individual patient. 0.5 Log is considered the cut-off for the intrinsic variability of the assay.
Abbreviations: CH, chronic hepatitis; NS, not significant.

Return To Article

table Of Contents

Copyright © 1999 by the American Association for the Study of Liver Diseases.

Hepatitis CentralHepatitis Central

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 27 Aug 2008